Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) Clinical research trials and Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS). Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) clinical trial. Human subjects frequently get the finest healthcare available for their Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.

Home > "M" Clinical Trials Conditions > Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)



Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

For Condition: Multiple Sclerosis
Status: Recruiting
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: Magnetic Resonance Imaging (MRI) is an advanced form of X-ray that uses magnetism to create pictures with excellent anatomical resolution. MRI is especially useful when studying the brain and nervous system. One type of MRI is done after a drug called gadolinium is injected into the vein. Gadolinium does not usually crossover from the bloodstream into the brain. However, when it does cross it can be seen by MRI. Therefore, when gadolinium is detected by MRI it means there has been some disruption of the barrier that normally exists between the blood and the brain. Researchers believe that a change in the blood-brain barrier is the first step in the development of new MS lesions. The overall goals of the study are to identify immunological processes that may contribute to the development of Multiple Sclerosis and to design specific therapies for the disease.
Details: Studies performed under 89-N-0045 are designed to examine the natural history of multiple sclerosis (MS) using MRI. In addition to studying the natural history of untreated patients, the natural history of patients receiving approved therapies of MS will be examined. Patients with either definite MS (based either on clinical or combined clinical and MRI criteria) or with an initial presentation of neurological dysfunction consistent with MS will be studied longitudinally by MRI. Disease activity on MRI will be assessed using several MRI measures of disease activity including the number of contrast enhancing lesions, the overall burden of disease, brain atrophy and measures to assess axonal damage. Patients will be assessed clinically and correlations between immunological and genetic factors and disease activity as seen clinically or by MRI will be studies. A second cohort of patients starting the use of approved therapy will also be examined. Patients referred to NIH prior to beginning approved therapy will be assessed with a series of three monthly MRIs to determine the level of pretreatment disease activity. After beginning approved therapy under the direction of their private physician, patients will be followed similarly to the natural history cohort. Immunological and genetic findings will be accessed before and during therapy in order to help establish the mechanisms of action of the therapies.
Eligibility:
Study Type:  Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Diagnosis of MS based on combined MRI and clinical crtieria OR, presenation with a clinically isolated syndrome consistent with MS and at least 2 abnormalities on MRI consistent with MS. 18-60 years of age Not currently receiving therapy for MS Able to give informed consent EXCLUSION CRITERIA: Diagnosis of neurological disease other than MS Significant medical condition other than MS Contraindication for MRI Pregnancy
Total Enrollment: 240

Location and Contact Information:

National Institute of Neurological Disorders and Stroke (NINDS) *Recruiting*
Bethesda,  Maryland,  20892
United States
Recruiting Patient  and Public Liaison Office 1-800-411-1222


Additional Information:
Study ID Numbers:  890045;  89-N-0045
Study Start Date: March 13, 1989
Record last reviewed: March 29, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001248

Other Multiple Sclerosis Studies:
1. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis

2. Evaluation of Lyme Disease: Clinical, Microbiological and Immunological Characteristics

3. Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients with Relapsing Multiple Sclerosis (MS)

4. Safety testing of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Laughter & Crying)

5. Registry to Evaluate Novantrone (R) Effects in Worsening Multiple Sclerosis (RENEW)

Related Studies:

Other Multiple Sclerosis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
Modify your Search

  Other Multiple Sclerosis Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103